

Search Results for Gene Therapy In Cancer

- 1: Heinio C, Sorsa S, Siurala M, Gronberg-Vaha-Koskela S, Havunen R, Haavisto E, Koski A, Hemminki O, Zafar S, Cervera-Carrascon V, Munaro E, Kanerva A, Hemminki A. Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs. *Human gene therapy*. 2019 Jun;Jun;30(6):740-752. doi: 10.1089/hum.2018.240. Epub 2019 Feb 28. PMID: 30672366; pmcid: Not Available. <http://www.ncbi.nlm.nih.gov/pubmed/30672366>.
- 2: Shim G, Kim D, Le QV, Park GT, Kwon T, Oh YK. Nonviral Delivery Systems for Cancer Gene Therapy: Strategies and Challenges. *Current gene therapy*. 2018;2018;18(1):3-20. doi: 10.2174/1566523218666180119121949. PMID: 29357792; pmcid: Not Available. <http://www.ncbi.nlm.nih.gov/pubmed/29357792>.
- 3: Farmer ZL, Kim ES, Carrizosa DR. Gene Therapy in Head and Neck Cancer. *Oral and maxillofacial surgery clinics of North America*. 2019 Feb;Feb;31(1):117-124. doi: 10.1016/j.coms.2018.08.006. Epub 2018 Oct 25. PMID: 30454787; pmcid: Not Available. <http://www.ncbi.nlm.nih.gov/pubmed/30454787>.
- 4: Zafir-Lavie I, Sherbo S, Goltsman H, Badinter F, Yeini E, Ofek P, Miari R, Tal O, Liran A, Shatil T, Krispel S, Shapir N, Neil GA, Benhar I, Panet A, Satchi-Fainaro R. Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases. *Journal of controlled release : official journal of the Controlled Release Society*. 2018 Dec 10;10;291:80-89. doi: 10.1016/j.jconrel.2018.10.017. Epub 2018 Oct 17. PMID: 30342077; pmcid: Not Available. <http://www.ncbi.nlm.nih.gov/pubmed/30342077>.
- 5: Sun W, Shi Q, Zhang H, Yang K, Ke Y, Wang Y, Qiao L. Advances in the techniques and methodologies of cancer gene therapy. *Discovery medicine*. 2019 Jan;Jan;27(146):45-55. doi: 10.1016/j.discovermedicine.2019.01.001. PMID: 30721651; pmcid: Not Available. <http://www.ncbi.nlm.nih.gov/pubmed/30721651>.
- 6: Neves AR, Sousa A, Faria R, Albuquerque T, Queiroz JA, Costa D. Cancer gene therapy mediated by RALA/plasmid DNA vectors: Nitrogen to phosphate groups ratio (N/P) as a tool for tunable transfection efficiency and apoptosis. *Colloids and surfaces. B, Biointerfaces*. 2020 Jan 1;1;185:110610. doi: 10.1016/j.colsurfb.2019.110610. Epub 2019 Oct 24. PMID: 31711736; pmcid: Not Available.

<http://www.ncbi.nlm.nih.gov/pubmed/31711736>.

7: Bottai G, Truffi M, Corsi F, Santarpia L. Progress in nonviral gene therapy for breast cancer and what comes next? Expert opinion on biological therapy. 2017 May;May;17(5):595-611. doi: 10.1080/14712598.2017.1305351. Epub 2017 Mar 22. PMID: 28330383; pmcid: Not Available. <http://www.ncbi.nlm.nih.gov/pubmed/28330383>.

8: Wang Q, Yang M, Zhang Y, Zhong L, Zheng X. Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer. Current gene therapy. 2019;2019;19(1):54-65. doi: 10.2174/1566523219666190307094713. PMID: 30848201; pmcid: Not Available. <http://www.ncbi.nlm.nih.gov/pubmed/30848201>.

9: Senapati D, Patra BC, Kar A, Chini DS, Ghosh S, Patra S, Bhattacharya M. Promising approaches of small interfering RNAs (siRNAs) mediated cancer gene therapy. Gene. 2019 Nov 30;30;719:144071. doi: 10.1016/j.gene.2019.144071. Epub 2019 Aug 24. PMID: 31454539; pmcid: Not Available. <http://www.ncbi.nlm.nih.gov/pubmed/31454539>.

10: Zhang WW, Li L, Li D, Liu J, Li X, Li W, Xu X, Zhang MJ, Chandler LA, Lin H, Hu A, Xu W, Lam DM. The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic. Human gene therapy. 2018 Feb;Feb;29(2):160-179. doi: 10.1089/hum.2017.218. PMID: 29338444; pmcid: Not Available. <http://www.ncbi.nlm.nih.gov/pubmed/29338444>.

11: Duplisea JJ, Mokkapati S, Plote D, Schluns KS, McConkey DJ, Yla-Herttuala S, Parker NR, Dinney CP. The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World journal of urology. 2019 Oct;Oct;37(10):2041-2049. doi: 10.1007/s00345-018-2553-7. Epub 2018 Nov 11. PMID: 30415317; pmcid: PMC6511323. <http://www.ncbi.nlm.nih.gov/pubmed/30415317>.

12: Lou B, Jin R, Cheng J, Wen X, Zhao P, Lin C. A hierarchical assembly strategy to engineer dextran-enveloped polyurethane nanopolyplexes for robust ovarian cancer gene therapy. Acta biomaterialia. 2018 Sep 15;15;78:260-273. doi: 10.1016/j.actbio.2018.07.049. Epub 2018 Jul 31. PMID: 30071349; pmcid: Not Available. <http://www.ncbi.nlm.nih.gov/pubmed/30071349>.

13: Bowman KR, Kim JH, Lim CS. Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer. Journal of ovarian research. 2019 Apr 30;30;12(1):38. doi: 10.1186/s13048-019-0514-4. PMID:

31039796; pmcid: PMC6492428. <http://www.ncbi.nlm.nih.gov/pubmed/31039796>.

14: Fu YR, Chen F, Luo Y, Yi YF. Nanoscale bubble ultrasound contrast agents-mediated suicide gene therapy system, Nanoscale bubble-LV5-YCD-TK/GCV/5-FC, effectively inhibits bladder cancer cell growth. *European review for medical and pharmacological sciences*. 2019 Jan;Jan;23(1):75-86. doi: 10.26355/eurrev_201901_16751. PMID: 30657549; pmcid: Not Available. <http://www.ncbi.nlm.nih.gov/pubmed/30657549>.

15: Li Y, Zhao S, Zhang F, Jin G, Zhou Y, Li P, Shin D, Yang X. Molecular imaging-monitored radiofrequency hyperthermia-enhanced intratumoral herpes simplex virus-thymidine kinase gene therapy for rat orthotopic ovarian cancer. *International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group*. 2020;2020;37(1):101-109. doi: 10.1080/02656736.2020.1711973. PMID: 31969028; pmcid: PMC7034662. <http://www.ncbi.nlm.nih.gov/pubmed/31969028>.

16: Rouanet M, Lebrin M, Gross F, Bournet B, Cordelier P, Buscail L. Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes. *International journal of molecular sciences*. 2017 Jun 8;ijms18061231. doi: 10.3390/ijms18061231. PMID: 28594388; pmcid: PMC5486054. <http://www.ncbi.nlm.nih.gov/pubmed/28594388>.

17: Tamura RE, de Luna IV, Lana MG, Strauss BE. Improving adenoviral vectors and strategies for prostate cancer gene therapy. *Clinics (Sao Paulo, Brazil)*. 2018 Aug 20;1):e476s. doi: 10.6061/clinics/2018/e476s. PMID: 30133562; pmcid: PMC6097088. <http://www.ncbi.nlm.nih.gov/pubmed/30133562>.

18: Wu J, Chen J, Feng Y, Tian H, Chen X. Tumor microenvironment as the "regulator" and "target" for gene therapy. *The journal of gene medicine*. 2019 Jul;Jul;21(7):e3088. doi: 10.1002/jgm.3088. Epub 2019 May 21. PMID: 30938916; pmcid: Not Available. <http://www.ncbi.nlm.nih.gov/pubmed/30938916>.

19: Tuppurainen L, Sallinen H, Karvonen A, Valkonen E, Laakso H, Liimatainen T, Hytonen E, Hamalainen K, Kosma VM, Anttila M, Yla-Herttuala S. Combined Gene Therapy Using AdsVEGFR2 and AdsTie2 With Chemotherapy Reduces the Growth of Human Ovarian Cancer and Formation of Ascites in Mice. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2017 Jun;Jun;27(5):879-886. doi: 10.1097/IGC.0000000000000973. PMID: 28498260; pmcid: Not Available. <http://www.ncbi.nlm.nih.gov/pubmed/28498260>.

20: Mohseni-Dargah M, Akbari-Birgani S, Madadi Z, Saghatchi F, Kaboudin B. Carbon nanotube-delivered iC9 suicide gene therapy for killing breast cancer cells in vitro. *Nanomedicine* (London, England). 2019 Apr;Apr;14(8):1033-1047. doi: 10.2217/nnm-2018-0342. Epub 2019 Mar 29. PMID: 30925115; pmcid: Not Available. <http://www.ncbi.nlm.nih.gov/pubmed/30925115>.